Cargando…

Histone Deacetylase 3: A Potential Therapeutic Target for Atherosclerosis

Atherosclerosis, the pathological basis of most cardiovascular disease, is characterized by plaque formation in the intima. Secondary lesions include intraplaque hemorrhage, plaque rupture, and local thrombosis. Vascular endothelial function impairment and smooth muscle cell migration lead to vascul...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jiang, Li-Ping, Yu, Xiao-Hua, Chen, Jin-Zhi, Hu, Mi, Zhang, Yang-Kai, Lin, Hui-Ling, Tang, Wan-Ying, He, Ping-Ping, Ouyang, Xin-Ping
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	JKL International LLC 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9116907/ https://www.ncbi.nlm.nih.gov/pubmed/35656103 http://dx.doi.org/10.14336/AD.2021.1116

Ejemplares similares

Histone Deacetylases (HDACs) and Atherosclerosis: A Mechanistic and Pharmacological Review
por: Chen, Xiaona, et al.
Publicado: (2020)

Histone Deacetylase Functions in Gastric Cancer: Therapeutic Target?
por: Badie, Amandine, et al.
Publicado: (2022)

Patho-epigenetics: histone deacetylases as targets of pathogens and therapeutics
por: Schator, Daniel, et al.
Publicado: (2021)

MicroRNA-296: a promising target in the pathogenesis of atherosclerosis?
por: Li, Heng, et al.
Publicado: (2018)

Histone Methyltransferase Enhancer of Zeste Homolog 2-Mediated ABCA1 Promoter DNA Methylation Contributes to the Progression of Atherosclerosis
por: Lv, Yun-Cheng, et al.
Publicado: (2016)

Histone deacetylase 10, a potential epigenetic target for therapy
por: Cheng, Fajuan, et al.
Publicado: (2021)

IRF5 is elevated in childhood-onset SLE and regulated by histone acetyltransferase and histone deacetylase inhibitors
por: Shu, Jin, et al.
Publicado: (2017)

Histone deacetylase 3, not histone deacetylase 2, interacts with the major immediate early locus of human cytomegalovirus
por: Huang, Ying, et al.
Publicado: (2011)

Class I and Class II Histone Deacetylases Are Potential Therapeutic Targets for Treating Pancreatic Cancer
por: Wang, Guan, et al.
Publicado: (2012)

Histone deacetylase-2: A potential regulator and therapeutic target in liver disease (Review)
por: Liu, Ya-Ru, et al.
Publicado: (2021)

Histone Deacetylases (HDACs): Promising Biomarkers and Potential Therapeutic Targets in Thymic Epithelial Tumors
por: Palamaris, Kostas, et al.
Publicado: (2023)

Aberrant expression of histone deacetylase 8 in endometriosis and its potential as a therapeutic target
por: Zheng, Hanxi, et al.
Publicado: (2023)

The class II histone deacetylases as therapeutic targets for Parkinson’s disease
por: Mazzocchi, Martina, et al.
Publicado: (2020)

A review of the therapeutic potential of histone deacetylase inhibitors in rhabdomyosarcoma
por: Selim, Omar, et al.
Publicado: (2023)

Histone Deacetylases and Histone Deacetylase Inhibitors in Neuroblastoma
por: Phimmachanh, Monica, et al.
Publicado: (2020)

Targeting Histone Deacetylases in Myeloid Cells Inhibits Their Maturation and Inflammatory Function With Limited Effects on Atherosclerosis
por: Luque-Martin, Rosario, et al.
Publicado: (2019)

Histone Deacetylase Inhibitor Trichostatin A Ameliorated Endotoxin-Induced Neuroinflammation and Cognitive Dysfunction
por: Hsing, Chung-Hsi, et al.
Publicado: (2015)

A Class 1 Histone Deacetylase with Potential as an Antifungal Target
por: Bauer, Ingo, et al.
Publicado: (2016)

Carbocisteine Improves Histone Deacetylase 2 Deacetylation Activity via Regulating Sumoylation of Histone Deacetylase 2 in Human Tracheobronchial Epithelial Cells
por: Song, Yun, et al.
Publicado: (2019)

Histone deacetylase inhibitors as novel anticancer therapeutics
por: Walkinshaw, D.R., et al.
Publicado: (2008)

Targeting of Histone Deacetylases to Reactivate Tumour Suppressor Genes and Its Therapeutic Potential in a Human Cervical Cancer Xenograft Model
por: Feng, Dingqing, et al.
Publicado: (2013)

Targeting histone deacetylases for the treatment of disease
por: Lawless, M W, et al.
Publicado: (2009)

Histone deacetylases as targets for antitrypanosomal drugs
por: Zuma, Aline A, et al.
Publicado: (2018)

Apoptosis Induction byHistone Deacetylase Inhibitors in Cancer Cells: Role of Ku70
por: Gong, Ping, et al.
Publicado: (2019)

Histone deacetylase 6 activity is critical for the metastasis of Burkitt’s lymphoma cells
por: Ding, Ning, et al.
Publicado: (2014)

Histone deacetylase activity is decreased in peripheral blood monocytes in patients with COPD
por: Chen, Yanwei, et al.
Publicado: (2012)

Targeting histone deacetylases for cancer therapy: Trends and challenges
por: Liang, Tao, et al.
Publicado: (2023)

Therapeutic Opportunities of Targeting Histone Deacetylase Isoforms to Eradicate Cancer Stem Cells
por: Lin, Peng-Chan, et al.
Publicado: (2018)

Targeting Histone Deacetylases in Idiopathic Pulmonary Fibrosis: A Future Therapeutic Option
por: Korfei, Martina, et al.
Publicado: (2022)

Role of Histone Deacetylases in the Pathogenesis of Salivary Gland Tumors and Therapeutic Targeting Options
por: Manou, Maria, et al.
Publicado: (2023)

Will histone deacetylase inhibitors require combination with other agents to fulfil their therapeutic potential?
por: Nolan, L, et al.
Publicado: (2008)

The Therapeutic Potential of Class I Selective Histone Deacetylase Inhibitors in Ovarian Cancer
por: Khabele, Dineo
Publicado: (2014)

New histone deacetylase inhibitors as potential therapeutic tools for advanced prostate carcinoma
por: Wedel, S A, et al.
Publicado: (2008)

Histone Deacetylase Inhibitors in Pediatric Brain Cancers: Biological Activities and Therapeutic Potential
por: Perla, Alexandre, et al.
Publicado: (2020)

Histone Deacetylase Enzymes as Potential Drug Targets in Cancer and Parasitic Diseases
por: Ouaissi, Mehdi, et al.
Publicado: (2006)

Histone deacetylase inhibitors: potential targets responsible for their anti-cancer effect
por: Dickinson, Michael, et al.
Publicado: (2010)

Histone Deacetylases as Epigenetic Targets for Treating Parkinson’s Disease
por: Li, Yan, et al.
Publicado: (2022)

Histone deacetylases play distinct roles in telomeric VSG expression site silencing in African trypanosomes
por: Wang, Qiao-Ping, et al.
Publicado: (2010)

New Insight in HDACs: Potential Therapeutic Targets for the Treatment of Atherosclerosis
por: Luan, Yi, et al.
Publicado: (2022)

Targeting Huntington’s disease through histone deacetylases
por: Gray, Steven G.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_93cqdpn6ce5vac8tn2sj6c5id0